Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 4/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 7/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740394 | 0.91 | PRKCQ (0.42) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL1740153 | 0.89 | PRKCQ (0.48) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL1740385 | 0.89 | PRKCQ (0.41) | PRKCQCCNT1CDK2CDK9SYK | |
| SCHEMBL1740824 | 0.87 | PRKCQ (0.51) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL1740600 | 0.85 | PRKCQ (0.56) | PRKCQEGFRITKAURKASYK | |
| SCHEMBL1739945 | 0.83 | PRKCQ (0.53) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL3496849 | 0.81 | PRKCQ (0.55) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL3494387 | 0.81 | PRKCQ (0.53) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL1739969 | 0.81 | EGFR (0.46) | PRKCQCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL1740277 | 0.81 | SYK (0.39) | PRKCQSYKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149475-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | claimed |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | claimed |
| US-8377924-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | claimed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | claimed |
| EP-2389373-B1 | DERIVATIVES OF N2-(3-PYRIDYL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9149475-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8377924-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2389373-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | Rigel Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110253835-A1 | AIRCRAFT INTERIOR LAVATORY | BE INTELLECTUAL PROPERTY, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010090875-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885CCNT1 3633/4885CCNE1 2947/4885 |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885CCNT1 3633/4885CCNE1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.